 Connection
Paul Bunn to Chemotherapy, Adjuvant
This is a "connection" page, showing publications Paul Bunn has written about Chemotherapy, Adjuvant.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.700 |
|
|
|
-
Solomon B, Mitchell JD, Bunn PA. Adjuvant chemotherapy for resected non-small-cell lung cancer. Oncology (Williston Park). 2005 Nov; 19(13):1685-97; discussion 1698-700, 1705.
Score: 0.234
-
Bunn PA, Kim ES. Improving the Care of Patients With Stage IB Non-Small-Cell Lung Cancer: Role of Prognostic Signatures and Use of Cell Cycle Progression Biomarkers. Clin Lung Cancer. 2015 Jul; 16(4):245-51.
Score: 0.112
-
Peled N, Oton AB, Hirsch FR, Bunn P. MAGE A3 antigen-specific cancer immunotherapeutic. Immunotherapy. 2009 Jan; 1(1):19-25.
Score: 0.073
-
Solomon B, Bunn PA. Adjuvant chemotherapy for non-small cell lung cancer. Cancer Invest. 2007 Jun; 25(4):217-25.
Score: 0.065
-
Bunn PA. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy. Clin Lung Cancer. 2004 Sep; 6(2):85-98.
Score: 0.054
-
Bunn PA. Early-stage NSCLC: the role of radiotherapy and systemic therapy. J Natl Compr Canc Netw. 2004 Sep; 2 Suppl 2:S31-40.
Score: 0.054
-
Bunn PA, Mault J, Kelly K. Adjuvant and neoadjuvant chemotherapy for non-small cell lung cancer: a time for reassessment? Chest. 2000 Apr; 117(4 Suppl 1):119S-122S.
Score: 0.040
-
Bunn PA, Kelly K. Systemic investigational therapies as adjuvants to surgery in patients with operable lung cancer. Semin Oncol. 1997 Jun; 24(3 Suppl 8):S8-46-S8-52.
Score: 0.033
-
Iyengar P, Kavanagh BD, Wardak Z, Smith I, Ahn C, Gerber DE, Dowell J, Hughes R, Abdulrahman R, Camidge DR, Gaspar LE, Doebele RC, Bunn PA, Choy H, Timmerman R. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol. 2014 Dec 01; 32(34):3824-30.
Score: 0.027
-
Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Bunn PA, Stemmerman G, Wells JD, Macdonald JS, Meyskens FL. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res. 1998 Mar 15; 58(6):1149-58.
Score: 0.009
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|